Literature DB >> 8004810

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

J A Kurtzhals1, A S Hey, A Jardim, M Kemp, K U Schaefer, E O Odera, C B Christensen, J I Githure, R W Olafson, T G Theander.   

Abstract

The T cell response to different Leishmania donovani antigens was investigated using peripheral blood mononuclear cells (PBMC) from Kenyans cured of visceral leishmaniasis and non-exposed Danes. Crude promastigote and amastigote antigens both induced proliferation and interferon-gamma (IFN-gamma) production in PBMC from cured patients, while cells from non-exposed donors gave weak responses. A similar pattern was induced by lipophosphoglycan-associated protein (LPGAP). By contrast, the major surface protease of Leishmania, gp63, induced only a weak proliferative response without IFN-gamma production in five of 17 samples from cured patients. Four of the five responding cultures produced IL-4, i.e. the response to this antigen was of the Th2 type. Furthermore, sera from acutely ill visceral leishmaniasis patients contained high levels of IgG antibodies to gp63. The Th2-like response to gp63 in patients cured of visceral leishmaniasis differs from the Th1-like response to the same antigen observed in patients cured of cutaneous leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004810      PMCID: PMC1534582          DOI: 10.1111/j.1365-2249.1994.tb06044.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

Review 2.  Functional heterogeneity of CD4+ T cells in leishmaniasis.

Authors:  F Y Liew
Journal:  Immunol Today       Date:  1989-02

3.  A tissue culture system for the growth of several species of Leishmania: growth kinetics and drug sensitivities.

Authors:  S Martinez; D L Looker; J J Marr
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

4.  Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis.

Authors:  B Galvão-Castro; J A Sá Ferreira; K F Marzochi; M C Marzochi; S G Coutinho; P H Lambert
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

5.  New perspectives on a subclinical form of visceral leishmaniasis.

Authors:  R Badaro; T C Jones; E M Carvalho; D Sampaio; S G Reed; A Barral; R Teixeira; W D Johnson
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

6.  T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis.

Authors:  M Castes; M Cabrera; D Trujillo; J Convit
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

7.  Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.

Authors:  M Belosevic; D S Finbloom; P H Van Der Meide; M V Slayter; C A Nacy
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

8.  Cloning of a gene encoding the immunodominant surface antigen of Leishmania donovani promastigotes.

Authors:  S Heath; M L Chance; M Hommel; J M Crampton
Journal:  Mol Biochem Parasitol       Date:  1987-04       Impact factor: 1.759

Review 9.  Lessons from Leishmania: a model for investigations of CD4+ subset differentiation.

Authors:  S L Reiner; R M Locksley
Journal:  Infect Agents Dis       Date:  1992-02

10.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

Authors:  E M Carvalho; R Badaró; S G Reed; T C Jones; W D Johnson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

View more
  19 in total

1.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 3.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

4.  Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis.

Authors:  K Kemp; M Kemp; A Kharazmi; A Ismail; J A Kurtzhals; L Hviid; T G Theander
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection.

Authors:  S Ajdary; M H Alimohammadian; M B Eslami; K Kemp; A Kharazmi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection.

Authors:  A Satoskar; H Bluethmann; J Alexander
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Authors:  Cynthia M Theodos; Robin V Morris; Jeanette V Bishop; Jeremy D Jones; W Robert McMaster; Richard G Titus
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.

Authors:  S Rafati; S Couty-Jouve; M H Alimohammadian; J A Louis
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

9.  Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors:  Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

10.  Combination of Mycobacterium indicus pranii and Heat-Induced Promastigotes Cures Drug-Resistant Leishmania Infection: Critical Role of Interleukin-6-Producing Classical Dendritic Cells.

Authors:  Somaditya Dey; Debarati Mukherjee; Sirin Salma Sultana; Suvadip Mallick; Aritri Dutta; Joydip Ghosh; Aabid Hussain; Biswajyoti Sarkar; Supratim Mandal; Pradyumna Patra; Bhaskar Saha; Chiranjib Pal
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.